Search

Your search keyword '"Turrini, M"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Turrini, M" Remove constraint Author: "Turrini, M"
213 results on '"Turrini, M"'

Search Results

1. Sexual dysfunction in multiple sclerosis: the impact of different MSISQ-19 cut-offs on prevalence and associated risk factors

2. Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy

3. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda

4. Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy

5. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

6. Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

7. Validation of the 'fitness criteria' for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)

8. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

9. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

10. S244: EFFECT OF ANTI-SPIKE NEUTRALIZING MONOCLONAL ANTIBODIES ON COVID-19 PROGRESSION AND TIME TO VIRAL CLEARANCE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SARS-COV-2 INFECTION: THE GIMEMA EXPERIENCE

11. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

12. Use of Plerixafor in Poor Mobilizer Patients with Myeloma and Lymphoma: Clonogenic Capacity and Engraftment Data

13. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

15. Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

16. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

17. Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study

18. Treatment of elderly patients with acute promyelocytic leukemia: A real life experience of the “rete ematologica lombarda”

19. PH plus STEM CELLS (SCS) IN CHRONIC MYELOID LEUKEMIA (CML): TO ERADICATE OR NOT TO ERADICATE, THIS IS THE QUESTION

20. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

21. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

23. SHOWCAVE: a multidisciplinary research project to quantify and mitigate the environmental impacts in tourist caves

24. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

25. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

28. Seduti a lavorare attorno al fuoco: un tentativo di riconoscere aree di attività in una porzione di suolo d’abitato ben conservata a Riparo Tagliente (Verona, Italy) - Sitting and working around a fireplace: an attempt to identify spatial organization from the portion of a well-preserved domestic area in Riparo Tagliente (Verona, Italy)

29. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

30. Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

31. Nilotinib induced bone marrow CD34+/lin–Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia

32. Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

33. Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment

34. Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

35. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

38. Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment

39. Corrigendum: Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia

42. Utilizzo dei sistemi GIS per la revisione di dati stratigrafici da depositi plurifase: il caso-studio di Riparo Tagliente (Stallavena di Grezzana, VR) - Application of GIS systems for the revision of stratigraphical data from multiphase deposits: the case-study of Riparo Tagliente (Stallavena di Grezzana, VR)

43. IDENTIFICATION OF MIRNA AND TARGET GENES IN THE TRANSCRIPTOME ANALYSIS OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AFTER 12 MONTHS OF NILOTINIB THERAPY

44. Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

45. Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

46. CLINICAL RELEVANCE OF RECURRENT ALLELE-SPECIFIC RECOMBINATION EXPRESSING THE WNT10BIVS1 ALLELE VARIANT IN ACUTE MYELOID LEUKEMIA

47. DIFFERENT SETS OF GENES WERE ASSOCIATED TO THE MOLECULAR RESPONSE AFTER 3 AND 6 MONTHS OF FIRST-LINE NILOTINIB TREATMENT BY MICROARRAY OF CD34+/LIN- CELLS OF CHRONIC PHASE CML PATIENTS AT DIAGNOSIS

50. DIFFERENT SETS OF GENES WERE ASSOCIATED TO THE MOLECULAR RESPONSE AFTER 3 AND 6 MONTHS OF FIRST-LINE NILOTINIB TREATMENT BY MICROARRAY OF CD34+/LIN- CELLS OF CHRONIC PHASE CML PATIENTS AT DIAGNOSIS

Catalog

Books, media, physical & digital resources